GlassScriptPhysician profile
Anthony Ramsey
NPI 1023216587
$4,251.51
in general payments reported to CMS, 2019-2025
43 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,568 · 2022: $197 · 2024: $13.54 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $597.37 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $446.78 | 2021-2025 | Airsupra, Breztri |
| Abbvie INC. | $371.00 | 2021-2025 | |
| Lilly USA, LLC | $305.07 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $225.74 | 2021-2025 | |
| Glaxosmithkline, LLC. | $165.55 | 2021-2025 | Shingrix |
| Abbott Laboratories | $162.82 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $162.58 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.30 | 2021-2025 | |
| Amgen INC. | $142.25 | 2021-2025 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.53 | 2021-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $138.24 | 2021 | |
| Neurocrine Biosciences, INC. | $82.77 | 2021-2022 | |
| Mylan Specialty L.P. | $76.59 | 2021 | |
| Sunovion Pharmaceuticals INC. | $73.05 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ramsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.